Journal articles on the topic 'Proteasome-like inhibitors'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Proteasome-like inhibitors.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Mitchell, Angela M., and R. Jude Samulski. "Mechanistic Insights into the Enhancement of Adeno-Associated Virus Transduction by Proteasome Inhibitors." Journal of Virology 87, no. 23 (September 11, 2013): 13035–41. http://dx.doi.org/10.1128/jvi.01826-13.
Full textWidjaja, Ivy, Erik de Vries, Donna M. Tscherne, Adolfo García-Sastre, Peter J. M. Rottier, and Cornelis A. M. de Haan. "Inhibition of the Ubiquitin-Proteasome System Affects Influenza A Virus Infection at a Postfusion Step." Journal of Virology 84, no. 18 (July 14, 2010): 9625–31. http://dx.doi.org/10.1128/jvi.01048-10.
Full textFidor, Anna, Katarzyna Cekała, Ewa Wieczerzak, Marta Cegłowska, Franciszek Kasprzykowski, Christine Edwards, and Hanna Mazur-Marzec. "Nostocyclopeptides as New Inhibitors of 20S Proteasome." Biomolecules 11, no. 10 (October 8, 2021): 1483. http://dx.doi.org/10.3390/biom11101483.
Full textKabore, Albert F., Kristin McCrea, James B. Johnston, and Spencer B. Gibson. "Proteasome Inhibiters Up-Regulate TRAIL/Apo2L and Its Receptors Significantly Contributing to Proteasome Inhibitor-Induced Apoptosis in Primary Chronic Lymphocytic Leukemia (CLL) Cells." Blood 104, no. 11 (November 16, 2004): 2810. http://dx.doi.org/10.1182/blood.v104.11.2810.2810.
Full textCrawford, Lisa J. A., Huib Ovaa, Brian Walker, Dharminder Chauhan, Kenneth C. Anderson, Treen C. M. Morris, and Alexandra E. Irvine. "Evaluation of the Specificity and Cytotoxicity of Three Proteasome Inhibitors." Blood 106, no. 11 (November 16, 2005): 3366. http://dx.doi.org/10.1182/blood.v106.11.3366.3366.
Full textParlati, Francesco, Monette Aujay, Siv Lise Bedringaas, Susan Demo, Bjorn Gjertsen, Eileen Goldstein, Jing Jiang, et al. "Anti-Tumor Activity of Immunoproteasome Selective Inhibitors." Blood 110, no. 11 (November 16, 2007): 1599. http://dx.doi.org/10.1182/blood.v110.11.1599.1599.
Full textKirk, Christopher J., Monette A. Aujay, Mark Ho, Jing Jiang, Guy J. Laidig, Evan R. Lewis, Yan Lu, et al. "Pharmacologic Evaluation of Orally Bioavailable Inhibitors of the 20S Proteasome." Blood 108, no. 11 (November 16, 2006): 3581. http://dx.doi.org/10.1182/blood.v108.11.3581.3581.
Full textHarding, C. V., J. France, R. Song, J. M. Farah, S. Chatterjee, M. Iqbal, and R. Siman. "Novel dipeptide aldehydes are proteasome inhibitors and block the MHC-I antigen-processing pathway." Journal of Immunology 155, no. 4 (August 15, 1995): 1767–75. http://dx.doi.org/10.4049/jimmunol.155.4.1767.
Full textSha, Zhe, Helena M. Schnell, Kerstin Ruoff, and Alfred Goldberg. "Rapid induction of p62 and GABARAPL1 upon proteasome inhibition promotes survival before autophagy activation." Journal of Cell Biology 217, no. 5 (March 13, 2018): 1757–76. http://dx.doi.org/10.1083/jcb.201708168.
Full textKraus, Marianne, Bobby Florea, Jürgen Bader, Nan Li, Paul Geurink, Wouter van der Linden, Hermen S. Overkleeft, and Christoph Driessen. "Selective Inhibition of the proteasome's β2 Catalytic Subunit Alone Does Not Induce Cytotoxicity, but Resensitizes Bortezomib-Refractory Myeloma Cells for Bortezomib Treatment." Blood 118, no. 21 (November 18, 2011): 2915. http://dx.doi.org/10.1182/blood.v118.21.2915.2915.
Full textTang, Guangqing, and Stephen H. Leppla. "Proteasome Activity Is Required for Anthrax Lethal Toxin To Kill Macrophages." Infection and Immunity 67, no. 6 (June 1, 1999): 3055–60. http://dx.doi.org/10.1128/iai.67.6.3055-3060.1999.
Full textTerpos, Evangelos, Eleni N. Tsakiri, Efstathios Kastritis, Tina Bagratuni, Vassilis G. Gorgoulis, Ioannis P. Trougakos, and Meletios A. Dimopoulos. "The Novel Proteasome Inhibitors Carfilzomib and Oprozomib Induce Milder Degenerative Effects Compared To Bortezomib When Administered Via Oral Feeding In An In Vivo Drosophila Experimental Model: A Biological Platform To Evaluate Safety/Efficacy Of Proteasome Inhibitors." Blood 122, no. 21 (November 15, 2013): 1930. http://dx.doi.org/10.1182/blood.v122.21.1930.1930.
Full textJia, Li, Ganga Gopinathan, Johanna T. Sukumar, and John G. Gribben. "Potentiation of Bortezomib-Induced Killing of Lymphoma Cells by Inhibition of Autophagy and Prevention of I-κBα Degradation." Blood 116, no. 21 (November 19, 2010): 116. http://dx.doi.org/10.1182/blood.v116.21.116.116.
Full textAhn, Won-Gyun, Yeejin Jeon, Yeong-In Yang, Jaeseung Kim, Seung-Joo Lee, Uwe Koch, Gunther Zischinsky, et al. "Abstract 416: A novel non-covalent and rapidly reversible proteasome inhibitor for multiple myeloma and various solid cancers." Cancer Research 82, no. 12_Supplement (June 15, 2022): 416. http://dx.doi.org/10.1158/1538-7445.am2022-416.
Full textShirazi, Fazal, Richard J. Jones, Ram K. Singh, Jianxuan Zou, Isere Kuiatse, Zuzana Berkova, Hua Wang, et al. "ActivatingKRAS,NRAS, andBRAFmutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma." Proceedings of the National Academy of Sciences 117, no. 33 (August 3, 2020): 20004–14. http://dx.doi.org/10.1073/pnas.2005052117.
Full textPonduru, Sridevi, Raymond Moellering, Edward Greenberg, John Paul Ying-Ching Shen, Benjamin Z. Stanton, and James E. Bradner. "Discovery and Characterization of Macrocyclic Thiopeptide Proteasome Inhibitors for Hematologic Malignancies." Blood 112, no. 11 (November 16, 2008): 3669. http://dx.doi.org/10.1182/blood.v112.11.3669.3669.
Full textSterz, Jan, Christian Jakob, Ulrike Kuckelkorn, Hannes A. Braun, Martin Kaiser, Claudia Fleissner, Lorenz Kleeberg, et al. "BSc2118, a Novel Proteasome Inhibitor, Shows Anti-Tumor Activity in Multiple Myeloma and Mantle Cell Lymphoma." Blood 108, no. 11 (November 16, 2006): 3475. http://dx.doi.org/10.1182/blood.v108.11.3475.3475.
Full textParlati, Francesco, Monette A. Aujay, Susan D. Demo, Eileen D. Goldstein, Jing Jiang, Christopher J. Kirk, Guy J. Laidig, et al. "Immunoproteasome-Selective Keto-Epoxide Inhibitors: Potential Therapeutic Agents for the Treatment of Hematological Disorders." Blood 108, no. 11 (November 16, 2006): 4392. http://dx.doi.org/10.1182/blood.v108.11.4392.4392.
Full textLai, Chao-Yang, Da-Wei Yeh, Chih-Hao Lu, Yi-Ling Liu, Li-Rung Huang, Cheng-Yuan Kao, Huan-Yuan Chen, et al. "Thiostrepton inhibits psoriasis-like inflammation induced by TLR7, TLR8, and TLR9." Journal of Immunology 196, no. 1_Supplement (May 1, 2016): 124.41. http://dx.doi.org/10.4049/jimmunol.196.supp.124.41.
Full textMa, Wanlong, Hagop Kantarjian, Susan O’Brien, Iman Jilani, Xi Zhang, Zeev Zestrov, Elihu Estey, et al. "Measurement and Clinical Relevance of Proteasome Enzymatic Activity in Plasma of Patients with Acute Lymphoblastic Leukemia." Blood 108, no. 11 (November 16, 2006): 4475. http://dx.doi.org/10.1182/blood.v108.11.4475.4475.
Full textHu, Zongyi, Zhensheng Zhang, Edward Doo, Olivier Coux, Alfred L. Goldberg, and T. Jake Liang. "Hepatitis B Virus X Protein Is both a Substrate and a Potential Inhibitor of the Proteasome Complex." Journal of Virology 73, no. 9 (September 1, 1999): 7231–40. http://dx.doi.org/10.1128/jvi.73.9.7231-7240.1999.
Full textBlackburn, Christopher, Kenneth M. Gigstad, Paul Hales, Khristofer Garcia, Matthew Jones, Frank J. Bruzzese, Cynthia Barrett, et al. "Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit." Biochemical Journal 430, no. 3 (August 27, 2010): 461–76. http://dx.doi.org/10.1042/bj20100383.
Full textDemo, Susan D., Monette A. Aujay, Eileen Goldstein, Guy J. Laidig, Francesco Parlati, Yan Lu, Kevin D. Shenk, et al. "Identification of Peptide Epoxy-Ketone Proteasome Inhibitors with Differential Active Site Selectivity." Blood 108, no. 11 (November 16, 2006): 4398. http://dx.doi.org/10.1182/blood.v108.11.4398.4398.
Full textDunys, Julie, Toshitaka Kawarai, Sherwin Wilk, Peter St. George-Hyslop, Cristine Alves Da Costa, and Frédéric Checler. "Catabolism of endogenous and overexpressed APH1a and PEN2: evidence for artifactual involvement of the proteasome in the degradation of overexpressed proteins." Biochemical Journal 394, no. 2 (February 10, 2006): 501–9. http://dx.doi.org/10.1042/bj20051197.
Full textBaldisserotto, Anna, Mauro Marastoni, Claudio Trapella, Riccardo Gavioli, Valeria Ferretti, Loretta Pretto, and Roberto Tomatis. "Glutamine vinyl ester proteasome inhibitors selective for trypsin-like (β2) subunit." European Journal of Medicinal Chemistry 42, no. 5 (May 2007): 586–92. http://dx.doi.org/10.1016/j.ejmech.2006.12.008.
Full textDemo, Susan D., Tonia J. Buchholz, Guy J. Laidig, Francesco Parlati, Kevin D. Shenk, Mark S. Smyth, Carol M. Sullivan, et al. "Biochemical and Cellular Characterization of the Novel Proteasome Inhibitor PR-171." Blood 106, no. 11 (November 16, 2005): 1588. http://dx.doi.org/10.1182/blood.v106.11.1588.1588.
Full textKuhn, Deborah J., Peter M. Voorhees, John S. Strader, Kevin D. Shenk, Congcong M. Sun, Susan D. Demo, Mark K. Bennett, and Robert Z. Orlowski. "Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma." Blood 106, no. 11 (November 16, 2005): 1576. http://dx.doi.org/10.1182/blood.v106.11.1576.1576.
Full textKuhn, Deborah J., Qing Chen, Peter M. Voorhees, John S. Strader, Kevin D. Shenk, Congcong M. Sun, Susan D. Demo, Mark K. Bennett, Fred W. van Leeuwen, and Robert Z. Orlowski. "The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance." Blood 108, no. 11 (November 16, 2006): 3461. http://dx.doi.org/10.1182/blood.v108.11.3461.3461.
Full textKuhn, Deborah J., Peter M. Voorhees, Qing Chen, John S. Strader, Frank Bruzzese, Jeffrey P. Ciavarri, Zhigen Hu, and Robert Z. Orlowski. "Development of Immunoproteasome-Specific Inhibitors as Novel Anti-Cancer Drugs." Blood 108, no. 11 (November 16, 2006): 3458. http://dx.doi.org/10.1182/blood.v108.11.3458.3458.
Full textPowell, Jason A., Melissa R. Pitman, Julia R. Zebol, Paul A. B. Moretti, Heidi A. Neubauer, Lorena T. Davies, Alexander C. Lewis, et al. "Kelch-like protein 5-mediated ubiquitination of lysine 183 promotes proteasomal degradation of sphingosine kinase 1." Biochemical Journal 476, no. 21 (November 11, 2019): 3211–26. http://dx.doi.org/10.1042/bcj20190245.
Full textChauhan, Dharminder, Ta-Hsiang Chao, Laurence Catley, Benjamin Nicholson, Mugdha Velanker, Teru Hideshima, Celia Berkers, et al. "In Vitro and In Vivo Proteasome Activity Profiles of Bortezomib and a Novel Proteasome Inhibitor NPI-0052." Blood 106, no. 11 (November 16, 2005): 3363. http://dx.doi.org/10.1182/blood.v106.11.3363.3363.
Full textParlati, Francesco, Susan J. Lee, Monette Aujay, Erika Suzuki, Konstantin Levitsky, James B. Lorens, David R. Micklem, et al. "Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome." Blood 114, no. 16 (October 15, 2009): 3439–47. http://dx.doi.org/10.1182/blood-2009-05-223677.
Full textPrösch, Susanna, Christina Priemer, Conny Höflich, Christa Liebenthal, Nina Babel, Detlev H. Krüger, and Hans-Dieter Volk. "Proteasome Inhibitors: A Novel Tool to Suppress Human Cytomegalovirus Replication and Virus-Induced Immune Modulation." Antiviral Therapy 8, no. 6 (August 1, 2002): 555–67. http://dx.doi.org/10.1177/135965350300800608.
Full textROBERTSON, John D., Kaushik DATTA, Shyam S. BISWAL, and James P. KEHRER. "Heat-shock protein 70 antisense oligomers enhance proteasome inhibitor-induced apoptosis." Biochemical Journal 344, no. 2 (November 24, 1999): 477–85. http://dx.doi.org/10.1042/bj3440477.
Full textHuang, Xiangao, Kathryn Bailey, Maurizio Di Liberto, Francesco Parlati, Ruben Niesvizky, Susan Demo, and Selina Chen-Kiang. "Induction of Sustained Early G1 Arrest by Selective Inhibition of CDK4 and CDK6 Primes Myeloma Cells for Synergistic Killing by Proteasome Inhibitors Carfilzomib and PR-047." Blood 112, no. 11 (November 16, 2008): 3670. http://dx.doi.org/10.1182/blood.v112.11.3670.3670.
Full textTrougakos, Ioannis P., Eleni-Dimitra Papanagnou, Tina Bagratuni, Efstathios Kastritis, Issidora S. Papassideri, Evangelos Terpos, and Meletios A. Dimopoulos. "Translating Findings of Proteasome Inhibitors Effects from the in VivoDrosophila Experimental Model to Humans: The Paradigm of the Molecular-Cellular Responses to Bortezomib and Carfilzomib." Blood 124, no. 21 (December 6, 2014): 4814. http://dx.doi.org/10.1182/blood.v124.21.4814.4814.
Full textChang, Tsui-Ling, and Chi-Hsien Wang. "Combination of quercetin and tannic acid in inhibiting 26S proteasome affects S5a and 20S expression, and accumulation of ubiquitin resulted in apoptosis in cancer chemoprevention." Biological Chemistry 394, no. 4 (April 1, 2013): 561–75. http://dx.doi.org/10.1515/hsz-2012-0277.
Full textKraus, Marianne, Jürgen Bader, Thomas Mehrling, and Christoph Driessen. "Edo- S101, a New Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Has Superior Activity Against Myeloma and B Cell Lymphoma and Strong Synergy with Proteasome Inhibitors in Vitro." Blood 124, no. 21 (December 6, 2014): 2249. http://dx.doi.org/10.1182/blood.v124.21.2249.2249.
Full textChauhan, Dharminder, Ajita Singh, Mohan Brahmandam, Klaus Podar, Teru Hideshima, Robert Schlossman, Paul Richardson, Nikhil Munshi, Michael Palladino, and Kenneth C. Anderson. "Combination of Proteasome Inhibitors Bortezomib and NPI-0052 Trigger In Vivo Synergistic Cytotoxicity in Multiple Myeloma." Blood 110, no. 11 (November 16, 2007): 2524. http://dx.doi.org/10.1182/blood.v110.11.2524.2524.
Full textYerlikaya, Azmi, Scot R. Kimball, and Bruce A. Stanley. "Phosphorylation of eIF2α in response to 26S proteasome inhibition is mediated by the haem-regulated inhibitor (HRI) kinase." Biochemical Journal 412, no. 3 (May 28, 2008): 579–88. http://dx.doi.org/10.1042/bj20080324.
Full textSpencer, Andrew, Michael Millward, Paul Mainwaring, Simon Harrison, Laurence Catley, Amanda Townsend, Shawgi Sukumaran, et al. "Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052." Blood 114, no. 22 (November 20, 2009): 2693. http://dx.doi.org/10.1182/blood.v114.22.2693.2693.
Full textArastu-Kapur, Shirin, Kevin Shenk, Francesco Parlati, and Mark K. Bennett. "Non-Proteasomal Targets of Proteasome Inhibitors Bortezomib and Carfilzomib." Blood 112, no. 11 (November 16, 2008): 2657. http://dx.doi.org/10.1182/blood.v112.11.2657.2657.
Full textMiller, Claudia P., Kechen Ban, Melanie E. Dujka, David J. McConkey, Mark Munsell, Michael Palladino, and Joya Chandra. "NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells." Blood 110, no. 1 (July 1, 2007): 267–77. http://dx.doi.org/10.1182/blood-2006-03-013128.
Full textTanaka, Yuko, Seiichi Okabe, Tetsuzo Tauchi, Yoshikazu Ito, and Kazuma Ohyashiki. "Targeting Insulin-like Growth Factor in Multiple Myeloma: Novel Strategies in the Treatment of Proteasome Inhibitor Resistant Cells." Blood 132, Supplement 1 (November 29, 2018): 5155. http://dx.doi.org/10.1182/blood-2018-99-114750.
Full textTong, Jian-Bo, Yuan-Yuan Li, Guo-Yan Jiang, and Kang-Nan Li. "Application of an R-group search technique in the molecular design of dipeptidyl boronic acid proteasome inhibitors." Journal of the Serbian Chemical Society 82, no. 9 (2017): 1025–37. http://dx.doi.org/10.2298/jsc161227047t.
Full textRos, Carlos, Christoph J. Burckhardt, and Christoph Kempf. "Cytoplasmic Trafficking of Minute Virus of Mice: Low-pH Requirement, Routing to Late Endosomes, and Proteasome Interaction." Journal of Virology 76, no. 24 (December 15, 2002): 12634–45. http://dx.doi.org/10.1128/jvi.76.24.12634-12645.2002.
Full textMa, Wanlong, Francis Giles, Susan O’Brien, Iman Jilani, Xi Zhang, Zeev Estrov, Elihu Estey, Alessandra Ferrajoli, Michael Keating, and Maher Albitar. "Variations in Proteasome Enzymatic Activities in Plasma of Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome and Their Value in Predicting Clinical Behavior." Blood 108, no. 11 (November 16, 2006): 4497. http://dx.doi.org/10.1182/blood.v108.11.4497.4497.
Full textMasdehors, Peggy, Hélène Merle-Béral, Karim Maloum, Satoshi Ömura, Henri Magdelénat, and Jozo Delic. "Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes." Blood 96, no. 1 (July 1, 2000): 269–74. http://dx.doi.org/10.1182/blood.v96.1.269.
Full textMasdehors, Peggy, Hélène Merle-Béral, Karim Maloum, Satoshi Ömura, Henri Magdelénat, and Jozo Delic. "Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes." Blood 96, no. 1 (July 1, 2000): 269–74. http://dx.doi.org/10.1182/blood.v96.1.269.013k10_269_274.
Full textSuzuki, Erika, Susan Demo, Shirin Arastu-Kapur, Christopher J. Kirk, and Mark K. Bennett. "Bortezomib-Resistant Cell Lines Have Increased Proteasome Levels but Remain Sensitive to Carfilzomib." Blood 114, no. 22 (November 20, 2009): 2852. http://dx.doi.org/10.1182/blood.v114.22.2852.2852.
Full text